Enovis CORP
ENOVNYSEHealthcare · Orthopedic, Prosthetic & Surgical Appliances & Supplies · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $2.25B | $2.11B | $1.71B | $1.56B | $1.43B | $1.12B |
| Operating income | −$1.12B | −$775.7M | −$65.7M | −$71.2M | −$62.8M | −$66.2M |
| Net income | −$1.18B | −$825.5M | −$33.3M | −$13.3M | $71.7M | $42.6M |
| Total assets | $3.83B | $4.72B | $4.51B | $4.27B | $8.52B | $7.35B |
| Total liabilities | $2.34B | $2.15B | $1.09B | $823.4M | $3.85B | $3.76B |
| Equity | $1.49B | $2.56B | $3.42B | $3.45B | $4.62B | $3.54B |
| EPS (diluted) | $-20.75 | $-14.93 | $-0.61 | $-0.25 | $1.40 | $0.93 |
| Shares out. | 57.0M | 54.6M | 54.3M | 161.3M | 118.5M | 118.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −50.0%
- Net margin
- −52.7%
- Return on equity
- −79.5%
- Return on assets
- −30.9%
- Return on capital (ROCE)
- −34.7%
- Liabilities / assets
- 61.1%
- Debt / equity
- 1.57×
- Book value / share
- $26.15
- Revenue growth (YoY)
- 6.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -1.51distress
- Accruals / assets
- −36.6%clean
- Beneish M-Score
- -4.33normal
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 2 warning● 3 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Vanguard Portfolio Management LlcPassive (13G)Apr 29, 2026
- Vanguard Capital Management LlcPassive (13G)Apr 29, 2026
- Vanguard Group IncPassive (13G)Mar 26, 2026
- Dimensional Fund Advisors LpPassive (13G)Jan 21, 2026
- American Century Investment Management IncPassive (13G)Aug 14, 2025
- Davenport & Co LlcPassive (13G)Aug 12, 2025
- Blackrock, Inc.Passive (13G)Jul 17, 2025
- T. Rowe Price Investment Management, Inc.Passive (13G)Jul 8, 2025
- Diamond Hill Capital Management IncPassive (13G)Feb 6, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Shirley BradyDirector | May 19, 2026 | Grant | 9,346 | $0.00 |
| Bodem Barbara W.Director | May 19, 2026 | Grant | 9,346 | $0.00 |
| Okala PhilipDirector | May 19, 2026 | Grant | 9,346 | $0.00 |
| Ortiz ChristineDirector | May 19, 2026 | Grant | 9,346 | $0.00 |
| Lalor Angela SDirector | May 19, 2026 | Grant | 9,346 | $0.00 |
| Perfall A ClaytonDirector | May 19, 2026 | Grant | 9,346 | $0.00 |
| Kelly LiamDirector | May 19, 2026 | Grant | 9,346 | $0.00 |
| Wienbar Sharon LDirector | May 19, 2026 | Grant | 9,346 | $0.00 |
| Vinnakota RajivDirector | May 19, 2026 | Grant | 9,346 | $0.00 |
| Mcdonald DamienOfficer — Chief Executive Officer | May 12, 2026 | Tax withholding | 12,634 | $25.99 |
| Berry Phillip Benjamin (Ben)Officer — SVP, Chief Financial Officer | May 12, 2026 | Tax withholding | 7,774 | $25.99 |
| Ortiz ChristineDirector | Mar 31, 2026 | Grant | 770 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 8.4M | 6.4 | -8.9% |
| Apr 30, 2026 | 9.2M | 9.2 | +7.5% |
| Apr 15, 2026 | 8.6M | 14.3 | +5.3% |
| Mar 31, 2026 | 8.1M | 9.5 | +2.5% |
| Mar 13, 2026 | 8.0M | 7.5 | -1.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer change · Shareholder voteMay 19, 2026
- Results of operationsMay 7, 2026
- Results of operationsFeb 26, 2026
- Regulation FD disclosureJan 12, 2026
- Director / officer changeDec 15, 2025
- Entered a material agreement · New financial obligationDec 10, 2025
- Director / officer changeNov 14, 2025
- Results of operationsNov 6, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Corporate family
Spin-offs from Enovis CORP (1)
From the spin-off filings we track. Follow a company to walk its own history.